4/A: Shaheen Wirk Reports Acquisition of Tvardi Therapeutics Shares Following Merger

Shaheen Wirk, a director of Tvardi Therapeutics, reports acquiring shares of common stock following the merger of Merger Sub with Legacy Tvardi.

Summary

• This Form 4/A filing reports changes in beneficial ownership for Shaheen Wirk, a director of Tvardi Therapeutics, Inc.
• The report details transactions occurring on April 15, 2025, related to the merger of Merger Sub with Legacy Tvardi.
• As a result of the merger, Legacy Tvardi became a wholly-owned subsidiary of Tvardi Therapeutics, Inc.
• Shaheen Wirk acquired 176,030 shares of common stock through Palkon Holdings, LLC and 263,164 shares through Palkon TT Holdings, LLC.
• These shares were received in exchange for Series B Preferred Stock of Legacy Tvardi, with a conversion ratio of 0.1341 shares of Tvardi Therapeutics common stock for each share of Legacy Tvardi stock.
• The reporting person disclaims beneficial ownership of these shares except to any pecuniary interests therein.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed about changes in ownership by a director.
• The merger impacts the share structure and potentially the value of the company.

Key Dates

Keywords

beneficial ownership, Tvardi Therapeutics, Shaheen Wirk, merger, Form 4, Legacy Tvardi, shares, stock